Infectious complications and transplant outcomes in durable left ventricular assist device patients receiving immunosuppressive therapy: case series
Open Access
- 1 June 2026
- journal article
- case report
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (6) , ytag455
Abstract
Background: The long-term prognosis of patients supported by durable left ventricular assist devices (LVAD) while receiving immunosuppressive therapy remains unclear. Underlying conditions such as cardiac sarcoidosis, recurrent myocarditis, or post-organ transplantation may necessitate concomitant immunosuppressive therapy during LVAD support. In particular, patients requiring prolonged immunosuppressive therapy exceeding low-dose corticosteroids represent a clinically challenging population in whom infectious complications and long-term outcomes have not been well characterized. Case summary: We retrospectively reviewed 241 consecutive LVAD recipients (HeartMate II and HeartMate 3) at a single centre (2013–24). Five patients (2.1%) required prolonged immunosuppressive therapy exceeding low-dose corticosteroids. Underlying cardiac conditions included myocarditis (n = 3), cardiac sarcoidosis (n = 1), and dilated cardiomyopathy following liver transplantation (n = 1). The mean duration of immunosuppressive therapy during LVAD support was 2.3 years (0.8–4.5 years). One patient developed LVAD-specific infections including driveline infection. Two underwent successful heart transplantation without perioperative complications. One was tapered to low-dose corticosteroid monotherapy due to a non-device-related infection, and two remained stable on LVAD support. Discussion: This case series underscores the complexity of managing LVAD patients requiring extended immunosuppressive therapy and highlights a unique and underreported patient population. Our findings suggest that successful heart transplantation may be achievable in immunosuppressed LVAD patients when supported by vigilant infection surveillance and individualized treatment strategies. This topic is of increasing clinical importance, particularly in regions where DT indications have recently been expanded.Keywords
This publication has 14 references indexed in Scilit:
- The second official report from Japanese registry for mechanical assisted circulatory support (J-MACS): first results of bridge to bridge strategyGeneral Thoracic and Cardiovascular Surgery, 2019
- Use of Durable Continuous-Flow Ventricular Assist Devices in Patients on ImmunosuppressionASAIO Journal, 2018
- Japanese registry for Mechanically Assisted Circulatory Support: First reportThe Journal of Heart and Lung Transplantation, 2017
- Impact of Ventricular Assist Device Complications on Posttransplant Survival: An Analysis of the United Network of Organ Sharing DatabaseThe Annals of Thoracic Surgery, 2013
- Driveline Infections in Left Ventricular Assist Devices: Implications for Destination TherapyThe Annals of Thoracic Surgery, 2012
- Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical TrialThe Annals of Thoracic Surgery, 2011
- Peripheral blood mononuclear cell transcriptome profiles suggest T-cell immunosuppression after uncomplicated mechanical circulatory support device surgeryHuman Immunology, 2009
- Cellular Immunity Impaired Among Patients on Left Ventricular Assist Device for 6 MonthsThe Annals of Thoracic Surgery, 2008
- Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implicationsThe Annals of Thoracic Surgery, 2003
- Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist de viceThe Lancet, 1999